EP Patent

EP2903601A1 — Dosage forms containing terbutaline sulphate

Assigned to Jagotec AG · Expires 2015-08-12 · 11y expired

What this patent protects

A modified release oral dosage form comprising an internal phase containing terbutaline sulphate and a pharmaceutically acceptable excipient, dispersed in an external phase comprising pharmaceutically acceptable excipients.

USPTO Abstract

A modified release oral dosage form comprising an internal phase containing terbutaline sulphate and a pharmaceutically acceptable excipient, dispersed in an external phase comprising pharmaceutically acceptable excipients.

Drugs covered by this patent

Patent Metadata

Patent number
EP2903601A1
Jurisdiction
EP
Classification
—
Expires
2015-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Jagotec AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.